Studies on the genetic pathogenesis of myasthenia gravis caused by CTLA-4 gene polymorphism

Chinese Journal of Medical Genetics

Volumn 21, Issue 6, 2004, Pages 574-578

  Mao, Hai Ting ^a   Wang, Xiong Biao ^b   Zhang, Ling ^a   Gu, Hong Tao ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CCAAT enhancer binding protein beta; Cytotoxic T lymphocyte associated antigen 4; Myasthenia gravis; Nuclear factor 1

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LECTIN; NUCLEAR FACTOR I;

ALLELE; ARTICLE; CHROMATIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC LINKAGE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; THYMOMA; THYMUS HYPERPLASIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CCAAT-ENHANCER-BINDING PROTEINS; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NFI TRANSCRIPTION FACTORS; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); THYMOMA; THYMUS HYPERPLASIA; THYMUS NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 10644224535     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Walunas TL, Lenschow DJ, Bakker CY. CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1994, 1: 405-413.
2. Huang D, Liu L, Noren K, et al. Genetic association of CTLA-4 to myasthenia gravis with thymoma. J Neuroimmunol, 1998, 88: 192-198.
3. Wang XB, Kakoulidou M, Qiu Q, et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immunity, 2002, 3: 46-49.
4. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab, 1997, 82: 4130-4132.
5. Deichman K, Heinzmann A, Bruggenolte E. An MseI RFLP in the human CTLA-4 promoter. Biochem Biophys Res Commun, 1996, 225: 817-818.
6. Hudson LL, Rocca K, Song YW, et al. CTLA-4 gene polymorphisms in systemic erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet, 2002, 111: 452-455.
7. Hironori U, Joanna MMH, Laura E, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 2003, 423: 506-511.
8. Pan L, Glenn ST, Jones CA, et al. Regulation of renin enhancer activity by nuclear factor 1 and Sp1/Sp3. Biochim Biophys Acta, 2003, 1625: 280-290.
9. Jones KA, Kadonaga JT, Rosenfeld PJ, et al. A cellular DNA binding protein that activates eukaryotic transcription and DNA replication. Cell, 1987, 48: 79-89.
10. Zahnow CA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res, 2002, 4: 113-121.